Screener
Tango Therapeutics TNGX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $157,828 | $112,279 |
| Marketable securities | 222,011 | 230,859 |
| Restricted cash | — | 428 |
| Prepaid expenses and other current assets | 12,488 | 10,190 |
| Total current assets | 392,327 | 353,756 |
| Property and equipment, net | 6,381 | 6,868 |
| Operating lease right-of-use assets | 34,652 | 35,624 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's restricted cash?
- Tango Therapeutics (TNGX) reported restricted cash of $0 in Q1 2026.
- How has Tango Therapeutics's restricted cash changed year-over-year?
- Tango Therapeutics's restricted cash decreased by 100.0% year-over-year, from $428K to $0.
- What is the long-term trend for Tango Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Tango Therapeutics's restricted cash has grown at a -28.4% compound annual growth rate (CAGR), from $2.28M to $428K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Tango Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude